Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MARS1 | P56192 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661745 | 0.85 | MAPT (0.45) | LMNAMARS1NPC1KDM4EMAPT | |
| SCHEMBL11903817 | 0.85 | NPC1 (0.42) | LMNAMARS1NPC1KDM4EMAPT | |
| SCHEMBL1922619 | 0.84 | CRHR1 (0.42) | MARS1NPC1KMT2AHTTALPL | |
| SCHEMBL12731280 | 0.83 | NPC1 (0.46) | NPC1USP2ALDH1A1HPGDKMT2A | |
| SCHEMBL1659930 | 0.79 | NPC1 (0.38) | LMNAMARS1NPC1USP2ALDH1A1 | |
| SCHEMBL1922297 | 0.79 | LMNA (0.48) | LMNAMARS1NPC1KDM4EMAPT | |
| SCHEMBL12731279 | 0.78 | NPC1 (0.41) | MARS1NPC1USP2ALDH1A1HPGD | |
| SCHEMBL12789037 | 0.76 | CNR1 (0.40) | NPC1MAPTALDH1A1HPGDHTT | |
| SCHEMBL12787456 | 0.74 | NPC1 (0.39) | MARS1NPC1USP2ALDH1A1HPGD | |
| SCHEMBL1922452 | 0.72 | CRHR1 (0.44) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2487177-A1 | PYRAZOLOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086898-A1 | PYRAZOLOOXAZOLE COMPOUND | CRHR1, MC2R, CRHR2 | LMNA 4788/4885MARS1 3106/4885NPC1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.